[PDF][PDF] A data locality optimizing algorithm
ME Wolf, MS Lam - Proceedings of the ACM SIGPLAN 1991 conference …, 1991 - dl.acm.org
This paper proposes an algorithm that improves the local-ity of a loop nest by transforming
the code via interchange, reversal, skewing and tiling. The loop transformation rrlgorithm is …
the code via interchange, reversal, skewing and tiling. The loop transformation rrlgorithm is …
A well-conditioned estimator for large-dimensional covariance matrices
Many applied problems require a covariance matrix estimator that is not only invertible, but
also well-conditioned (that is, inverting it does not amplify estimation error). For large-…
also well-conditioned (that is, inverting it does not amplify estimation error). For large-…
The causal pathways linking health literacy to health outcomes
MK Paasche-Orlow, MS Wolf - American journal of health …, 2007 - ingentaconnect.com
Objective : To provide an evidence-based review of plausible causal pathways that could best
explain well-established associations between limited health literacy and health outcomes…
explain well-established associations between limited health literacy and health outcomes…
[BOOK][B] Subsampling in the IID Case
In this chapter, a general theory for the construction of confidence intervals or regions is
presented. Much of what is presented is extracted from Politis and Romano (1992c, 1994b). The …
presented. Much of what is presented is extracted from Politis and Romano (1992c, 1994b). The …
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non–small cell lung cancer: a randomized trial
…, A Sandler, KS Albain, D Cella, MK Wolf… - Jama, 2003 - jamanetwork.com
ContextMore persons in the United States die from non–small cell lung cancer (NSCLC) than
from breast, colorectal, and prostate cancer combined. In preclinical testing, oral gefitinib …
from breast, colorectal, and prostate cancer combined. In preclinical testing, oral gefitinib …
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
RG Amado, M Wolf, M Peeters, E Van Cutsem… - Journal of clinical …, 2008 - air.unimi.it
Purpose: Panitumumab, a fully human antibody against the epidermal growth factor
receptor (EGFR), has activity in a subset of patients with metastatic colorectal cancer (mCRC). …
receptor (EGFR), has activity in a subset of patients with metastatic colorectal cancer (mCRC). …
Gefitinib in combination with paclitaxel and carboplatin in advanced non–small-cell lung cancer: a phase III trial—INTACT 2
…, R Rosell, I Oliff, JA Reeves, MK Wolf… - Journal of Clinical …, 2004 - ascopubs.org
Purpose Preclinical studies indicate that gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington,
DE), an orally active epidermal growth factor receptor tyrosine kinase inhibitor, may …
DE), an orally active epidermal growth factor receptor tyrosine kinase inhibitor, may …
Gefitinib in combination with gemcitabine and cisplatin in advanced non–small-cell lung cancer: a phase III trial—INTACT 1
…, J Grous, JS Ochs, SD Averbuch, MK Wolf… - Journal of Clinical …, 2004 - ascopubs.org
Purpose The purpose of this study was to determine whether the addition of the epidermal
growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839; AstraZeneca, …
growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839; AstraZeneca, …
[BOOK][B] Powell on real property
MA Wolf - 2013 - lexisnexis.com
… General Editor Michael Allan Wolf … Allan Wolf, Chapter 40 discusses private express
trusts, charitable trusts, … Section 1.07[1] written by Michael Allan Wolf provides an overview of …
trusts, charitable trusts, … Section 1.07[1] written by Michael Allan Wolf provides an overview of …
[PDF][PDF] Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory …
…, J Maurel, G Richardson, M Wolf… - Journal of clinical …, 2007 - Citeseer
Purpose Panitumumab is a fully human monoclonal antibody directed against the epidermal
growth factor receptor (EGFR). We compared the activity of panitumumab plus best …
growth factor receptor (EGFR). We compared the activity of panitumumab plus best …